Cargando…

The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination

Detalles Bibliográficos
Autores principales:	Shi, Rui, Chai, Yan, Duan, Xiaomin, Bi, Xiaoshan, Huang, Qingrui, Wang, Qihui, Tan, Shuguang, Gao, George F., Zhu, Jianhua, Yan, Jinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058617/ https://www.ncbi.nlm.nih.gov/pubmed/32296041 http://dx.doi.org/10.1038/s41392-020-0121-2

Ejemplares similares

CD47-Blocking Antibodies and Atherosclerosis
por: Ryan, John J.
Publicado: (2016)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

CD47 on artificial structures
por: Schütz, Christian
Publicado: (2015)

CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis
por: Kojima, Yoko, et al.
Publicado: (2016)

Role of CD47 in Hematological Malignancies
por: Eladl, Entsar, et al.
Publicado: (2020)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals
por: Li, Yang, et al.
Publicado: (2022)

CD47 prevents the elimination of diseased fibroblasts in scleroderma
por: Lerbs, Tristan, et al.
Publicado: (2020)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

CD47 as a promising therapeutic target in oncology
por: Zhao, Hai, et al.
Publicado: (2022)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
por: Betancur, Paola A., et al.
Publicado: (2017)

Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
por: Yang, Hongcheng, et al.
Publicado: (2019)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release
por: Lian, Shu, et al.
Publicado: (2019)

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer
por: Bian, Yanlin, et al.
Publicado: (2022)

Significance of CD47 expression in gastric cancer
por: Sudo, Tomoya, et al.
Publicado: (2017)

Regulation of CD47 expression in cancer cells
por: Huang, Can-Yu, et al.
Publicado: (2020)

CD47 (Cluster of differentiation 47): an anti-phagocytic receptor with a multitude of signaling functions
por: Leclair, Pascal, et al.
Publicado: (2020)

A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
por: Zeng, Dadi, et al.
Publicado: (2016)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
por: Wu, Hao, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
por: Wang, Rongjuan, et al.
Publicado: (2023)

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
por: Candas-Green, Demet, et al.
Publicado: (2020)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
por: Yang, Yun, et al.
Publicado: (2023)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Upregulation of CD47 in Regulatory T Cells in Atopic Dermatitis
por: Lee, Nara, et al.
Publicado: (2016)

Is CD47 an innate immune checkpoint for tumor evasion?
por: Liu, Xiaojuan, et al.
Publicado: (2017)

Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma
por: Petralia, Maria Cristina, et al.
Publicado: (2019)

CD47 Deficiency Ameliorates Ocular Autoimmune Inflammation
por: Okunuki, Yoko, et al.
Publicado: (2021)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer
por: Shi, Chenyang, et al.
Publicado: (2022)

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
por: Dheilly, Elie, et al.
Publicado: (2017)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Hendriks, Mark A.J.M., et al.
Publicado: (2021)

Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy
por: Liu, Hongchuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o75v1a9ok51p7q5p3ra6etdah2